CR20190236A - Compuestos terapéuticos y métodos para utilizarlos - Google Patents
Compuestos terapéuticos y métodos para utilizarlosInfo
- Publication number
- CR20190236A CR20190236A CR20190236A CR20190236A CR20190236A CR 20190236 A CR20190236 A CR 20190236A CR 20190236 A CR20190236 A CR 20190236A CR 20190236 A CR20190236 A CR 20190236A CR 20190236 A CR20190236 A CR 20190236A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- therapeutic compounds
- compounds
- het
- variables
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La invención proporciona un compuesto de fórmula I: o una sal farmacéuticamente aceptable de este, donde las variables X, Y1-Y5, R1, R2, R3, R4 y Het poseen el significado descrito en la presente, y composiciones que contienen dichos compuestos y métodos para utilizar dichos compuestos y composiciones.The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1-Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016102263 | 2016-10-17 | ||
PCT/CN2017/103499 WO2018072602A1 (en) | 2016-10-17 | 2017-09-26 | Therapeutic compounds and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20190236A true CR20190236A (es) | 2019-09-09 |
Family
ID=62018232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20190236A CR20190236A (es) | 2016-10-17 | 2017-09-26 | Compuestos terapéuticos y métodos para utilizarlos |
Country Status (21)
Country | Link |
---|---|
US (2) | US10457654B2 (es) |
EP (1) | EP3526205A4 (es) |
JP (1) | JP2019532077A (es) |
KR (1) | KR20190078587A (es) |
CN (1) | CN110072855A (es) |
AR (1) | AR109964A1 (es) |
AU (1) | AU2017347549A1 (es) |
BR (1) | BR112019007763A2 (es) |
CA (1) | CA3039853A1 (es) |
CL (1) | CL2019001041A1 (es) |
CO (1) | CO2019004978A2 (es) |
CR (1) | CR20190236A (es) |
IL (1) | IL265955A (es) |
MA (1) | MA46546A (es) |
MX (1) | MX2019004232A (es) |
PE (1) | PE20190980A1 (es) |
PH (1) | PH12019500839A1 (es) |
RU (1) | RU2019114964A (es) |
SG (1) | SG11201903348UA (es) |
TW (1) | TW201821412A (es) |
WO (1) | WO2018072602A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
EP3759098A1 (en) * | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
WO2020248123A1 (en) * | 2019-06-11 | 2020-12-17 | Merck Sharp & Dohme Corp. | Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
CN112745279A (zh) * | 2019-10-31 | 2021-05-04 | 杭州澳医保灵药业有限公司 | 醋甲唑胺及其类似物及其在正常压力脑积水的治疗中的应用 |
CN115784922B (zh) * | 2022-11-09 | 2024-03-29 | 苏州爱玛特生物科技有限公司 | 一种(2s)-2-氨基-4-(环丙基/环丁基)丁酸的制备方法 |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3705185A (en) | 1969-04-14 | 1972-12-05 | Minnesota Mining & Mfg | N-aroyl sulfonamides |
US4130566A (en) | 1977-10-27 | 1978-12-19 | Sumitomo Chemical Company, Limited | Process for producing 5-carboxy-2-acetylthiophene |
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
GB8524157D0 (en) | 1984-10-19 | 1985-11-06 | Ici America Inc | Heterocyclic amides |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
DK24089D0 (da) | 1989-01-20 | 1989-01-20 | Hans Bundgaard | Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups |
GB8911854D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
AU690529B2 (en) | 1992-11-23 | 1998-04-30 | Hoechst Marion Roussel, Inc. | Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds |
NZ275318A (en) | 1993-11-19 | 1999-06-29 | Parke Davis & Co | 5,6-dihydro-4-substitutedpyran-2-one and -pyrid-2-one derivatives and the corresponding cyclohex-2-enone analogues |
US5573653A (en) | 1994-07-11 | 1996-11-12 | Sandoz Ltd. | Electrochemical process for thiocyanating aminobenzene compounds |
WO1996006837A1 (fr) | 1994-08-30 | 1996-03-07 | Sankyo Company, Limited | Isoxazoles |
US5753653A (en) | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
US6608105B2 (en) | 2000-12-18 | 2003-08-19 | Meiji Dairies Corporation | TNF-α production inhibitor comprising kavalactone as an active ingredient |
KR100789567B1 (ko) | 2001-11-06 | 2007-12-28 | 동화약품공업주식회사 | 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도 |
DE10201550A1 (de) | 2002-01-17 | 2003-07-31 | Merck Patent Gmbh | Phenoxy-Piperidine |
ATE449099T1 (de) | 2002-08-08 | 2009-12-15 | Memory Pharm Corp | Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren |
US7132425B2 (en) | 2002-12-12 | 2006-11-07 | Hoffmann-La Roche Inc. | 5-substituted-six-membered heteroaromatic glucokinase activators |
AU2004230316A1 (en) | 2003-04-15 | 2004-10-28 | Pfizer Inc. | Alpha substituted carboxylic acid as PPAR modulators |
CN1863785A (zh) | 2003-08-08 | 2006-11-15 | 沃泰克斯药物股份有限公司 | 在疼痛的治疗中用作钠或钙通道阻断剂的杂芳基氨基磺酰基苯基衍生物 |
PE20050358A1 (es) * | 2003-08-08 | 2005-05-16 | Vertex Pharma | Composiciones referidas a inhibidores de canales ionicos regulados por voltaje |
EP1668002B1 (en) | 2003-10-03 | 2009-11-11 | Portola Pharmaceuticals, Inc. | 2,4-dioxo-3-quinazolinylaryl sulfonylureas |
US7081539B2 (en) | 2004-03-25 | 2006-07-25 | Dainippon Sumitomo Pharma Co., Ltd. | One-pot process for the preparation of 1,2-benzisoxazole-3-methanesulfonamide |
CN1993335A (zh) | 2004-07-30 | 2007-07-04 | 默克公司 | 代谢型谷氨酸受体的二氢茚酮增效剂 |
ATE462697T1 (de) | 2004-08-12 | 2010-04-15 | Amgen Inc | Bisaryl-sulfonamide |
EP1812429A4 (en) | 2004-09-29 | 2010-07-21 | Portola Pharm Inc | SUBSTITUTED 2H-1,3-BENZOXAZIN-4 (3H) -ONE |
JP2008189549A (ja) | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US7915410B2 (en) | 2005-09-09 | 2011-03-29 | Bristol-Myers Squibb Company | Acyclic IKur inhibitors |
DE602006005699D1 (de) | 2005-10-19 | 2009-04-23 | Hoffmann La Roche | N-phenyl-phenylacetamid-nichtnukleosidinhibitoren reverser transkriptase |
EP1951667A2 (en) | 2005-11-23 | 2008-08-06 | Ligand Pharmaceuticals, Inc. | Thrombopoietin activity modulating compounds and methods |
AR058296A1 (es) | 2005-12-09 | 2008-01-30 | Kalypsys Inc | Inhibidores de histona desacetilasa y composicion farmaceutica |
US8841483B2 (en) | 2006-04-11 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
ES2377821T3 (es) | 2006-10-11 | 2012-04-02 | Amgen Inc. | Compuestos de imidazo- y triazolo-piridina y métodos de uso de los mismos. |
WO2008094602A2 (en) | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | 1-h-pyrazolo (3,4b) pyrimidine derivatives and their use as modulators of mitotic kinases |
RU2009133336A (ru) | 2007-02-05 | 2011-03-20 | Ксенон Фармасьютикалз Инк. (Ca) | Пиридопиримидиноновые соединения, применимые при лечении заболеваний или состояний, опосредуемых натриевыми каналами |
JP5361857B2 (ja) | 2007-03-23 | 2013-12-04 | ファイザー・リミテッド | イオンチャネルの阻害剤 |
CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
CA2693552A1 (en) | 2007-06-07 | 2008-12-11 | Astellas Pharma Inc. | Pyridone compound |
US20090012103A1 (en) | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
US8124610B2 (en) * | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
TW200911766A (en) | 2007-07-13 | 2009-03-16 | Astrazeneca Ab | New compounds |
EP2184278A4 (en) | 2007-08-10 | 2011-08-03 | Nippon Chemiphar Co | P2X4 RECEIVER ANTAGONIST |
GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
CA2728511A1 (en) | 2008-06-23 | 2009-12-30 | Astellas Pharma Inc. | Sulfonamide compounds or salts thereof |
WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
KR101345497B1 (ko) | 2009-01-12 | 2013-12-31 | 이카겐, 인코포레이티드 | 설폰아미드 유도체 |
EP2464645B1 (en) | 2009-07-27 | 2017-07-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
WO2011016234A1 (en) | 2009-08-04 | 2011-02-10 | Raqualia Pharma Inc. | Picolinamide derivatives as ttx-s blockers |
TW201117809A (en) | 2009-09-25 | 2011-06-01 | Astellas Pharma Inc | Substituted amide compounds |
WO2011059042A1 (ja) | 2009-11-12 | 2011-05-19 | 武田薬品工業株式会社 | 芳香環化合物 |
US8471034B2 (en) | 2009-11-18 | 2013-06-25 | Concert Pharmaceuticals, Inc. | Niacin prodrugs and deuterated versions thereof |
TW201139406A (en) | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
RU2585763C2 (ru) | 2010-02-12 | 2016-06-10 | Нивалис Терапьютикс,Инк. | Новые ингибиторы s-нитрозоглутатионредуктазы |
WO2011153588A1 (en) | 2010-06-10 | 2011-12-15 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
US20120004714A1 (en) | 2010-06-30 | 2012-01-05 | Ryan Kleve | Lead having coil electrode with preferential bending region |
US9279003B2 (en) | 2010-07-07 | 2016-03-08 | Purdue Pharma L.P. | Analogs of sodium channel peptide toxin |
EP2590951B1 (en) | 2010-07-09 | 2015-01-07 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
EP2590972B1 (en) | 2010-07-09 | 2015-01-21 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
JP5860045B2 (ja) | 2010-07-09 | 2016-02-16 | ファイザー・リミテッドPfizer Limited | 化合物 |
CA2800971A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
EP2593432B1 (en) | 2010-07-12 | 2014-10-22 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
US9096500B2 (en) | 2010-07-12 | 2015-08-04 | Pfizer Limited | Acyl sulfonamide compounds |
EP2593427B1 (en) | 2010-07-12 | 2014-12-24 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
CA2804351A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
EP2593434A1 (en) | 2010-07-16 | 2013-05-22 | Purdue Pharma LP | Pyridine compounds as sodium channel blockers |
SG188438A1 (en) | 2010-09-13 | 2013-05-31 | Novartis Ag | Triazine-oxadiazoles |
WO2012039657A1 (en) | 2010-09-22 | 2012-03-29 | Astrazeneca Ab | Novel chromane compound for the treatment of pain disorders |
WO2012085650A1 (en) | 2010-12-22 | 2012-06-28 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
WO2012095781A1 (en) | 2011-01-13 | 2012-07-19 | Pfizer Limited | Indazole derivatives as sodium channel inhibitors |
SI2670752T1 (sl) | 2011-02-02 | 2016-10-28 | Vertex Pharmaceuticals Incorporated | Pirolopirazin-spirociklični piperidin amidi kot modulatorji ionskih kanalčkov |
SG193241A1 (en) | 2011-03-25 | 2013-10-30 | Glaxosmithkline Ip No 2 Ltd | Cyclopropylamines as lsd1 inhibitors |
MX2014001851A (es) * | 2011-08-17 | 2014-10-24 | Amgen Inc | Inhibidores del canal de heteroarilo sodio. |
WO2013056232A2 (en) | 2011-10-13 | 2013-04-18 | Case Western Reserve University | Rxr agonists compounds and methods |
CA2852796A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp. | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
BR112014010368A2 (pt) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc | biaril éter sulfonamidas e seu uso como agentes terapêuticos |
KR20140091022A (ko) | 2011-10-31 | 2014-07-18 | 제논 파마슈티칼스 인크. | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
WO2013072758A1 (en) | 2011-11-15 | 2013-05-23 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
WO2013086229A1 (en) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
ES2593533T3 (es) | 2011-12-15 | 2016-12-09 | Pfizer Limited | Derivados de sulfonamida |
US20150291514A1 (en) | 2012-01-04 | 2015-10-15 | Pfizer Limted | N-Aminosulfonyl Benzamides |
JP2015083542A (ja) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | 3位置換プロリン誘導体 |
US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
WO2013122897A1 (en) * | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
WO2013146969A1 (ja) | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | 新規二置換シクロヘキサン誘導体 |
AU2013266398A1 (en) * | 2012-05-22 | 2015-01-22 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
CN104797555B (zh) | 2012-07-06 | 2017-12-22 | 基因泰克公司 | N‑取代的苯甲酰胺及其使用方法 |
CN104640843A (zh) | 2012-07-19 | 2015-05-20 | 大日本住友制药株式会社 | 1-(环烷基羰基)脯氨酸衍生物 |
EP2911668A4 (en) | 2012-10-26 | 2016-07-20 | Merck Sharp & Dohme | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-CONTROLLED SODIUM CHANNELS |
CN104869992A (zh) | 2012-10-26 | 2015-08-26 | 默沙东公司 | 具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物 |
US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
RS56015B1 (sr) | 2013-01-31 | 2017-09-29 | Vertex Pharma | Piridon amidi kao modulatori natrijumovih kanala |
US20140296266A1 (en) | 2013-03-01 | 2014-10-02 | Gilead Sciences, Inc. | Therapeutic compounds |
CN105263490B (zh) | 2013-03-14 | 2018-05-22 | 基因泰克公司 | 取代的三唑并吡啶及其使用方法 |
WO2014142221A1 (ja) * | 2013-03-14 | 2014-09-18 | 第一三共株式会社 | 呼吸器疾患用薬 |
JP6449845B2 (ja) | 2013-03-15 | 2019-01-09 | クロモセル コーポレイション | 疼痛の処置のためのナトリウムチャネルモジュレーター |
JP6227112B2 (ja) | 2013-03-15 | 2017-11-08 | ジェネンテック, インコーポレイテッド | 置換ベンゾオキサゾールとその使用方法 |
WO2015051043A1 (en) | 2013-10-01 | 2015-04-09 | Amgen Inc. | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors |
CR20160296A (es) | 2013-11-27 | 2016-09-20 | Genentech Inc | Benzamidas sustituidas y métodos para usarlas |
WO2015077905A1 (en) | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels |
KR20180008761A (ko) | 2015-05-22 | 2018-01-24 | 제넨테크, 인크. | 치환된 벤즈아미드 및 이의 이용 방법 |
CN108349963B (zh) * | 2015-11-13 | 2021-03-30 | 株式会社大熊制药 | 钠通道阻断剂 |
CN108699015A (zh) | 2015-12-18 | 2018-10-23 | 默沙东公司 | 对电压门控性钠通道具有选择性活性的羟基烷基胺-和羟基环烷基胺-取代的二胺-芳基磺胺化合物 |
US10519147B2 (en) | 2015-12-18 | 2019-12-31 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
US10442778B2 (en) | 2016-03-22 | 2019-10-15 | Merck Sharp & Dohme Corp. | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels |
US10668067B2 (en) | 2016-07-20 | 2020-06-02 | Amgen Inc. | Pyridine sulfonamides |
-
2017
- 2017-09-26 MA MA046546A patent/MA46546A/fr unknown
- 2017-09-26 JP JP2019520725A patent/JP2019532077A/ja active Pending
- 2017-09-26 MX MX2019004232A patent/MX2019004232A/es unknown
- 2017-09-26 WO PCT/CN2017/103499 patent/WO2018072602A1/en active Application Filing
- 2017-09-26 EP EP17863182.6A patent/EP3526205A4/en not_active Withdrawn
- 2017-09-26 CA CA3039853A patent/CA3039853A1/en not_active Abandoned
- 2017-09-26 KR KR1020197013820A patent/KR20190078587A/ko not_active Application Discontinuation
- 2017-09-26 CN CN201780077257.9A patent/CN110072855A/zh active Pending
- 2017-09-26 BR BR112019007763A patent/BR112019007763A2/pt not_active IP Right Cessation
- 2017-09-26 CR CR20190236A patent/CR20190236A/es unknown
- 2017-09-26 AU AU2017347549A patent/AU2017347549A1/en not_active Abandoned
- 2017-09-26 RU RU2019114964A patent/RU2019114964A/ru not_active Application Discontinuation
- 2017-09-26 PE PE2019000843A patent/PE20190980A1/es unknown
- 2017-09-26 SG SG11201903348UA patent/SG11201903348UA/en unknown
- 2017-10-17 TW TW106135501A patent/TW201821412A/zh unknown
- 2017-10-17 AR ARP170102884A patent/AR109964A1/es unknown
- 2017-10-31 US US15/799,771 patent/US10457654B2/en not_active Expired - Fee Related
-
2019
- 2019-04-10 IL IL265955A patent/IL265955A/en unknown
- 2019-04-16 PH PH12019500839A patent/PH12019500839A1/en unknown
- 2019-04-16 CL CL2019001041A patent/CL2019001041A1/es unknown
- 2019-05-15 CO CONC2019/0004978A patent/CO2019004978A2/es unknown
- 2019-09-19 US US16/576,569 patent/US20200115354A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL265955A (en) | 2019-05-30 |
SG11201903348UA (en) | 2019-05-30 |
US10457654B2 (en) | 2019-10-29 |
CN110072855A (zh) | 2019-07-30 |
CO2019004978A2 (es) | 2019-07-31 |
EP3526205A4 (en) | 2020-05-27 |
MA46546A (fr) | 2021-05-05 |
MX2019004232A (es) | 2019-08-01 |
PH12019500839A1 (en) | 2019-06-24 |
CA3039853A1 (en) | 2018-04-26 |
RU2019114964A3 (es) | 2021-01-29 |
WO2018072602A1 (en) | 2018-04-26 |
JP2019532077A (ja) | 2019-11-07 |
US20180105504A1 (en) | 2018-04-19 |
AU2017347549A1 (en) | 2019-05-02 |
US20200115354A1 (en) | 2020-04-16 |
CL2019001041A1 (es) | 2019-06-21 |
KR20190078587A (ko) | 2019-07-04 |
PE20190980A1 (es) | 2019-07-09 |
BR112019007763A2 (pt) | 2019-07-02 |
RU2019114964A (ru) | 2020-11-17 |
EP3526205A1 (en) | 2019-08-21 |
AR109964A1 (es) | 2019-02-06 |
TW201821412A (zh) | 2018-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20190236A (es) | Compuestos terapéuticos y métodos para utilizarlos | |
CL2019003086A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
CR20170237A (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
CL2020000610A1 (es) | Compuestos de bisamida que activan el sarcómero y sus usos. | |
ECSP16067303A (es) | Heteroarilos y usos de estos | |
BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
CR20140413A (es) | Inhibidores de serina/treonina cinasa | |
MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
BR112019007108A2 (pt) | misturas herbicidas | |
UY36712A (es) | Derivados de pirimidiniloxi benceno como herbicidas | |
UY37941A (es) | Derivados de bencimidazol y sus usos | |
BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
WO2018039077A8 (en) | Therapeutic compounds | |
BR112019008415A2 (pt) | composto de piridona e inibidor de c-met, composição farmacêutica e uso dos mesmos | |
CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
MX2020004842A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
MX2018016339A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
CO2018003909A2 (es) | Compuestos terapéuticos y sus métodos de uso | |
BR112016023991A2 (pt) | ativadores de herg policíclicos | |
CY1119540T1 (el) | Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt |